Banner Banner

A single-cell lung cancer atlas reveals cellular and molecular drivers of metastasis and clinical outcome

Philipp Jurmeister
Philipp Keyl
Liliana Harris Mochmann
Linda Bergmayr
Konstanze Schleich
Edgar Chimal Calderon
Fabian Engelhardt-Schott
Doreen Klingler
Dražen Papić
Janine Wolff
Rebecca Fritz
Julius Keyl
Sabine Merkelbach-Bruse
Alexander Quaas
Georg Schlachtenberger
Matthias Heldwein
Jens-Carsten Rückert
Gabriel Dernbach
Nils Reinmuth
Christian Grohé
Reinhard Büttner
David Horst
Nikolaj Frost
Patrick Nikolaus Harter
Klaus-Robert Müller
Simon Schallenberg
Frederick Klauschen

November 12, 2026

Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, characterized by extensive cellular and molecular heterogeneity. Here, to capture this complexity, we present LuCaS+, a multicenter single-cell RNA sequencing atlas comprising over 2.5 million nuclei from 454 clinically annotated patients with NSCLC with long-term follow-up. LuCaS+ consists of a discovery dataset (Berlin and Cologne, 364 patients) and an independent validation dataset (Munich, 90 patients). Leveraging this dataset, we identified tumor subpopulations with high metastatic potential associated with oncogenic signaling, immune evasion and epithelial–mesenchymal transition. In early-stage adenocarcinoma (lung adenocarcinoma), these cells showed strong prognostic value. Integrating tumor and microenvironmental cell profiles improved survival prediction across all stages, identifying distinct tumor–immune–stromal interaction patterns. These included monocyte- and fibroblast-driven inflammation (lung adenocarcinoma), VEGF–TGFβ-mediated angiogenic feedback loops (lung squamous cell carcinoma) and immune-permissive niches promoting antitumor immunity. LuCaS+ offers a clinically anchored single-cell resource to enable personalized, biology-driven therapies in NSCLC.